HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loeb, J. A. Search for Related Content PubMed PubMed Citation Articles by Loeb, J. A.

Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis

From the Department of Neurology and the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan.

Address correspondence and reprint requests to Dr. Jeffrey A. Loeb, Department of Neurology, Wayne State University School of Medicine, 421 E. Canfield Ave., #3122, Detroit, MI 48201 jloeb{at}med.wayne.edu

Based on the efficacy of immunomodulatory therapies in patients with multiple sclerosis (MS), much of the research and thinking about pathogenesis and treatment has traditionally focused on suppressing the immune system. Whatever the cause, recent studies have rekindled the notion that neurologic dysfunction in patients with MS relates best to the degree of neuronal (axonal) and glial damage. Therefore, as a means to understand the pathogenesis of MS and to develop biologically targeted new therapeutics, a greater understanding of axoglial biology is needed. Central to axoglial biology are protein regulatory factors that include gliotrophic factors such as the neuregulins and neurotrophic factors that communicate between these cell types and are critical for nervous system development. Unfortunately, the track record of neurotrophic factors for treating other neurologic disorders has not been impressive, in part because of a failure to aim these factors at appropriate pathophysiologic targets. Although future therapeutic strategies in MS may be able to take advantage of these factors, such strategies will require an in-depth understanding of how these factors signal and how they are naturally targeted to axons and glia in both health and disease.

This supplement was supported by an educational grant from Teva Neuroscience. BioScience Communications contributed to the editorial refinement of this article and to the production of this supplement. Authors may have accepted honoraria for their supplement contributions.

Disclosure:. The author reports no conflict of interest.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology.

This article has been cited by other articles:

				G. Birnbaum, T. P. Leist, and F. D. Lublin Commentary I: Pathophysiologic construct for neuronal degeneration/regeneration in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S2 - S4. [Full Text] [PDF]